Document:

SECURITIES
PURCHASE AGREEMENT

 

This
Securities Purchase Agreement (this “Agreement”) is dated as of December 22, 2015, between InnSuites Hospitality
Trust, an Ohio unincorporated real estate investment trust (the “Trust”), and each purchaser identified on
the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the
“Purchasers”).

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933,
as amended (the “Securities Act”), the Trust desires to issue and sell to each Purchaser, and each Purchaser,
severally and not jointly, desires to purchase from the Trust, securities of the Trust as more fully described in this Agreement.

 

NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration
the receipt and adequacy of which are hereby acknowledged, the Trust and each Purchaser agree as follows:

 

1. On
December 22, 2015 or another date that is mutually acceptable to the parties (the “Closing Date”), upon the
terms and subject to the conditions set forth herein, the Trust agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase hereunder, (i) that aggregate number of Shares of Beneficial Interest of the Trust set forth on such Purchaser’s
signature page hereto (the “Shares”) (which aggregate number of Shares for all Purchasers shall be 21,929),
at a purchase price of $2.28 per Share and the aggregate principal amount set forth on such Purchaser’s signature page hereto
(the “Subscription Amount”). Each Purchaser shall deliver to the Trust, via wire transfer, certified check
of immediately available funds, or another method acceptable to the Trust, an amount equal to such Purchaser’s Subscription
Amount as set forth on its signature page hereto. Upon satisfaction of the covenants and conditions set forth herein, the closing
of the transactions contemplated herein (the “Closing”) shall occur at the offices of the Trust or such other
location as the parties shall mutually agree.

 

2. Representations
and Warranties of the Purchasers. As of the date hereof and as of the Closing Date, each of the Purchasers hereby represents and
warrants to the Trust as follows:

 

(a) The
Purchaser is agreeing to purchase the Shares solely for the Purchaser’s own account and for investment and not with a view
toward the distribution thereof. The Purchaser understands that the Shares which the Purchaser is purchasing will not be registered
under the Securities Act or applicable state securities laws and, therefore, cannot be resold unless registered under the Securities
Act and applicable state securities laws, or unless an exemption from registration is available. The Purchaser acknowledges that
because of the restrictions on the transferability of the Shares, the Purchaser must bear the economic risk of the Purchaser’s
investment in the Shares.

 

(b) The
Purchaser has read carefully and is familiar with the Trust’s filings with the Securities and Exchange Commission (the “Commission”),
including its last annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, and understands the contents thereof,
including the risks associated with an investment in the Shares; the Purchaser has been provided the opportunity, to the Purchaser’s
satisfaction, to ask questions and receive answers concerning the terms and conditions of the offering of the Shares; all of the
Purchaser’s questions have been answered to the Purchaser’s satisfaction; and the Purchaser has been supplied with
all additional information requested and deemed necessary by the Purchaser to make an investment decision with respect to the
Shares.

 

    	 	1	 

    	 	 	 

    

 

(c) The
Purchaser presently qualifies as an “accredited investor” as such term is defined in Rule 501 under the Securities
Act.

 

(d) Except
as set forth in the Trust’s filings with the Commission, the Purchaser is not an “affiliate” of the Trust (it
being understood that an “affiliate” means any person or entity that, directly or indirectly through one or
more intermediaries, controls or is controlled by or is under common control with a person as such terms are used in and construed
under Rule 405 and Rule 144 under the Securities Act).

 

(e) The
Purchaser: (i) is familiar with investments of this type and has such knowledge, sophistication and experience in business and
financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares; (ii) does
not have an overall commitment to investments that are not readily marketable that is disproportionate to the Purchaser’s
net worth, and the Purchaser’s investment in the Shares will not cause such overall commitment to become excessive; and
(iii) has adequate net worth and means of providing for the Purchaser’s current needs and personal contingencies to sustain
a complete loss of the Purchaser’s investment in the Shares.

 

(f) The
Purchaser is fully aware that the Shares are being issued and sold in reliance upon the exemption provided for by Section 4(a)(2)
of the Securities Act and similar exemptions provided under state securities laws on the grounds that no public offering is involved
and that the representations, warranties and agreements set forth in this Agreement are essential to the claiming of such exemptions.

 

(g) The
Purchaser: (i) is purchasing the Shares with the Purchaser’s own funds and not with the funds of any other person, firm
or entity; (ii) is acquiring the Shares for the Purchaser’s own account; and (iii) has no reason to anticipate a change
in personal circumstances, financial or otherwise, that would cause the Purchaser to sell or distribute, or necessitate or require
any sale or distribution of, the Shares, and no other person, firm or entity has or will have any beneficial interest in the Shares.

 

(h) The
Purchaser will cooperate in filing, or authorizing the filing on the Purchaser’s behalf, of any report or form required
by the Commission or any state securities agencies to be filed in connection with the purchase of the Shares.

 

(i) The
person(s) executing this Agreement, has the right, power, authority and capacity to sign and deliver this Agreement and perform
all obligations hereunder on behalf of the Purchaser. The Purchaser understands, represents and warrants that this Agreement is
binding on the Purchaser and enforceable in accordance with its terms.

 

(j) The
Purchaser, if a business entity, represents and warrants that the execution and delivery of this Agreement and the consummation
of the transactions contemplated hereby have been duly authorized by the Purchaser. The Purchaser, if a business entity, was not
formed for the specific purpose of acquiring the Shares to which this Agreement relates.

 

    	 	2	 

    	 	 	 

    

 

(l) The
Purchaser is presently a bona fide resident of the state set forth on the signature page hereof and the address set forth thereon
is the Purchaser’s true and correct residence. The Purchaser has no present intention of becoming a resident of any other
state or jurisdiction.

 

(m) The
Purchaser understands that nothing in this Agreement or any other materials presented to the Purchaser in connection with the
purchase and sale of the Shares constitutes legal, tax or investment advice. The Purchaser has consulted such legal, tax and investment
advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Shares.

 

(n) The
Purchaser is not purchasing the Shares as a result of any advertisement, article, notice or other communication regarding the
Shares published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar
or any other general solicitation or general advertisement. The Purchaser has had a pre-existing relationship with the Trust prior
to contemplating an investment contemplated herein.

 

3. Representations
and Warranties of the Trust. As of the date hereof and as of the Closing Date, the Trust hereby represents and warrants to each
of the Purchasers as follows:

 

(a) The
Trust is an entity duly organized, validly existing and in good standing under the laws of the State of Ohio, with the requisite
power and authority to perform its obligations under this Agreement and to consummate the transactions contemplated hereby.

 

(b) Subject
to Section 4(a)(C) hereof, (i) the Trust has the requisite power and authority to enter into and perform its obligations under
this Agreement; (ii) the execution, delivery and performance of this Agreement have been duly authorized by all necessary action
on the part of the Trust; and (iii) assuming the due authorization, execution and delivery by each of the Purchasers, this Agreement
will, when executed, constitute valid and binding obligations of the Trust in accordance with its terms.

 

(c) The
Trust currently has an unlimited number of Shares of Beneficial Interest available for issuance under its Declaration of Trust.
As of the date hereof, the Trust has approximately 8,259,093 Shares of Beneficial Interest issued and outstanding.

 

(d) Subject
to Section 4(a)(C) hereof, the Shares issuable to the Purchasers pursuant to this Agreement have been duly authorized and, when
issued to the Purchasers pursuant to this Agreement, will be validly issued, fully paid and nonassessable and free and clear of
any and all encumbrances (other than restrictions upon transfer imposed by applicable securities laws). Assuming the accuracy
of the representations of the Purchasers set forth in this Agreement, the Shares issuable to the Purchasers hereunder will be
issued in compliance with all applicable federal and state securities laws.

 

4. Closing
Conditions. 

 

(a) The
obligations of the Trust hereunder in connection with the Closing are subject to the following conditions being met:

 

a.
The accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Purchasers
contained herein; 

 

    	 	3	 

    	 	 	 

    

 

b.
All obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have
been performed; 

 

c.
The approval by the NYSE MKT of the Trust’s additional listing application regarding the aggregate number of the Shares
to be issued to the Purchasers in this offering shall have been obtained; and

 

d.
The delivery by each Purchaser of the signed copy of this Agreement and the Subscription Amount.

 

(b) The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
met:

 

a.
The accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Trust contained
herein;

 

b.
All obligations, covenants and agreements of the Trust required to be performed at or prior to the Closing Date shall have been
performed; 

 

c.
The approval by the NYSE MKT of the Trust’s additional listing application regarding the aggregate number of the Shares
to be issued to the Purchasers in this offering shall have been obtained; and

 

d.
The delivery by the Trust of the signed copy of this Agreement and the stock certificates for the Shares. 

 

5. Each
of the Purchasers, severally and not jointly, agrees to indemnify and hold harmless the Trust and its founders, trustees, officers,
agents, attorneys, representatives and other shareholders from any and all losses to any of them arising out of the breach of
any of such Purchaser’s agreements, representations or warranties set forth in this Agreement. All representations, warranties
and agreements contained in this Agreement and the indemnification contained in this section shall survive the purchase and sale
of the Shares.

 

6. Each
of the Purchaser’s understands that this Agreement is binding on the Purchaser, and any heirs, personal representatives,
successors or assigns of the Purchaser, and may not be canceled, revoked, transferred or assigned by the Purchaser or by any of
them. This Agreement may only be amended by prior written agreement between the Trust and the Purchaser.

 

7. Certificates
for the Shares shall bear a legend substantially in the following form:

 

THIS
SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD IN THE ABSENCE OF (I) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR (II) PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AS EVIDENCED
BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, THE SUBSTANCE
OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE TRUST.

 

    	 	4	 

    	 	 	 

    

 

8. This
Agreement contains the entire understanding of the parties with respect to the subject matter hereof and supersedes all prior
agreements and understandings, oral or written, with respect to such matters. If any term, provision, covenant or restriction
of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of
the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be
affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an
alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant
or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void
or unenforceable.

 

9. This
Agreement will be governed by and construed in accordance with the laws of the State of Ohio, notwithstanding any conflict of
law provision to the contrary. Any dispute or disagreement related to this Agreement or the purchase of the Shares by the Purchasers
shall be heard by a state or federal court located in Cleveland, Ohio, and the Purchaser hereby expressly waives the Purchaser’s
right to object to such venue on the grounds of lack of personal jurisdiction or forum non-conveniens.

 

[Signature
Page Follows]

 

    	 	5	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the parties have executed and delivered this Agreement, which may be executed in one or more counterparts, as
of the date set forth above.

 

	INDIVIDUALS SIGN HERE	 	Subscription Amount: $49,998.12 
	 	 	 
	Sign Here:	 	 	Number of Shares: 21,929
	Print Name:	 	 	 

 

	ENTITIES SIGN HERE:	 	 
	 	 	 	Address: 1625 E Northern Avenue # 105 
	Name of Entity:	Rare Earth Financial, LLC	 	Phoenix, Arizona 85020 
	Sign Here:	/s/ James Wirth	 	 
	Print Name:	Rare Earth Financial, LLC	 	 
	Title:	Managing Member	 	 
	 	 	 	 
	Accepted by:	 	 	 

 

	INNSUITES HOSPITALITY TRUST	 	 
	 	 	 	 
	Sign Here:	/s/ James Wirth	 	 
	Print Name:	James Wirth	 	 
	Title:	CEO and Trustee	 	 

 

    	 	6EX-10.1

 Exhibit 10.1 

AMENDMENT TO ASSET TRANSFER AND LICENSE AGREEMENT 

This AMENDMENT (the “Amendment”) is dated as of December 23, 2015 (the “Amendment Effective Date”) to
the Asset Transfer and License Agreement (the “Agreement”) dated as of April 10, 2015 between Alkermes Pharma Ireland Limited, a private limited company incorporated in Ireland (registered number 448848) whose registered
address is Connaught House, 1 Burlington Road, Dublin 4, Ireland (“APIL”), and Recro Gainesville LLC, a Massachusetts limited liability company (successor to DV Technology LLC, “Purchaser,” and Purchaser shall
include, after the Amendment Effective Date, any entity possessing the obligations of Purchaser set forth in the Agreement). Defined terms used but not defined herein shall have the meaning ascribed to such terms in the Agreement. 

RECITALS: 
 WHEREAS, APIL and DV
Technology LLC entered into the Agreement pursuant to which APIL sold and assigned and Purchaser purchased and acquired certain assets of APIL, and DV Technology was granted a license to certain intellectual property of APIL; 

WHEREAS, DV Technology was merged with and into Purchaser, and Purchaser succeeded the obligations of DV Technology under the Agreement; and

 WHEREAS, pursuant to this Amendment, APIL and Purchaser desire that APIL transfer and assign to Purchaser certain of the intellectual
property of APIL that was previously licensed to Purchaser; 
 NOW, THEREFORE, in consideration of the respective premises, mutual covenants
and agreements of the parties hereto, and other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the parties hereto agree as follows: 
  

	 	1.	Definition of Zogenix Patents. As of the Amendment Effective Date, the definition of Zogenix Patents shall be replaced with the following: 

Zogenix Patents shall mean Abuse Resistant Patents and all patents and patent applications licensed by APIL to Zogenix as of the
Effective Date pursuant to the Zogenix Agreements, including those listed in Exhibit A-4 hereto. 
  

	 	2.	Deletion of Section 3(c) and Addition of Section 2(f). As of the Amendment Effective Date, Section 3(c) shall be deleted in its entirety and a new Section 2(f) shall be added to the Agreement
which shall read as follows: 

 Abuse Resistant Patents License. Notwithstanding the foregoing and subject to the terms
and conditions of the Agreement, effective the Amendment Effective Date, Purchaser hereby grants back to APIL an exclusive, worldwide, fully-paid-up, perpetual license under the Abuse Resistant Patents, with the right to sublicense (through multiple
tiers), to develop, make, have made, use, sell, offer to sell and import pharmaceutical products for the treatment of any human disease, disorder or condition, subject to the Zogenix Agreements and the Paladin Agreements. Notwithstanding anything to
the contrary contained in this Amendment or the Agreement, the parties hereby agree that this license shall extend until the expiration or invalidation of all Abuse Resistant Patents. 

	 	3.	Addition to Section 2(e). The following paragraph shall be added to Section 2(e) of the Agreement: 

Notwithstanding the foregoing, to the extent that Purchaser declines to Enforce any issued patent within the Abuse Resistant Patents with
respect to an infringing activity within the scope of the exclusive license granted to APIL pursuant to Section 2(f), APIL shall have the option to Enforce such patent, at its own cost and expense, provided that APIL can demonstrate to
Purchaser’s reasonable satisfaction that (i) permitting such infringing activity would have a materially adverse effect on APIL’s and its sublicensees’ sales of the product exclusively licensed under such patent, and
(ii) based on a due care determination, including obtaining competent legal advice, the infringing activity exists. In such cases, APIL will have sole control of such enforcement at its cost and expense. To the extent necessary, Purchaser will
cooperate with APIL, at APIL’s cost and expense, to carry out such enforcement, including joining as a party. Purchaser shall also have the right, at its option and its cost and expense, to join in any such enforcement action taken by APIL,
subject to APIL’s right to control such action. For any recovery from an enforcement action involving a patent within the Abuse Resistant Patents, Purchaser shall be entitled to fifty percent (50%) of such recovery, provided however, that
fifty percent (50%) of the legal fees, costs and expenses of such enforcement action incurred by APIL shall be deducted from Purchaser’s portion of the recovery. APIL shall not enter into any settlement agreement regarding the Abuse
Resistant Patents without Purchaser’s prior written consent which shall not be unreasonably withheld, delayed or conditioned. 
  

	 	4.	Replacement of Section 3(f). As of the Amendment Effective Date, Section 3(f) shall be replaced with the following: 

Prosecution. APIL shall have the right to Prosecute any issued patent or pending patent application within the Nanotechnology Patents
and the OCR Patents at its sole discretion and cost and expense. APIL shall keep Purchaser reasonably informed of all activities during the course of such prosecution and provide Purchaser with copies of material correspondence and filings relating
to such activities. At APIL’s request and expense, Purchaser will cooperate to Prosecute the Nanotechnology Patents and the OCR Patents. 

If in addition to APIL’s activities to Prosecute the Nanotechnology Patents, Purchaser wishes with respect to any Nanotechnology Patent
listed in subsection A-2.6 of Exhibit A-1 to have a divisional, continuation or continuation-in-part application filed that solely claims a compound, composition, method of making or method of using compounds or compositions within the scope
of Purchaser’s exclusive license hereunder, then Purchaser shall notify APIL and, subject to APIL’s approval, which shall not unreasonably withheld, delayed or conditioned, APIL will use commercially reasonable efforts to Prosecute such
patent 

  
 -2- 

 
application, at Purchaser’s cost and expense. Promptly upon receipt, APIL will provide Purchaser with all patent office documents relating to such prosecution, and will also provide drafts
of responses to office actions and other substantive filings with any patent office regarding such patent application sufficiently in advance of their submission to enable review and comment by Purchaser. APIL will consider in good faith all
comments timely made by Purchaser. 
  

	 	5.	Replacement of Section 3(g). As of the Amendment Effective Date, Section 3(g) shall be replaced with the following: 

Enforcement. APIL shall have the first right to Enforce any issued patent within the Nanotechnology Patents and the OCR Patents. To the
extent necessary, Purchaser will cooperate with APIL, at APIL’s cost and expense, to carry out such enforcement, including joining as a party. All costs and expenses of such enforcement action will be borne by APIL, and APIL shall retain any
recovery from such an enforcement action. Notwithstanding the foregoing, Purchaser may voluntarily join such enforcement action if the action pertains to an Infringing Activity (as defined below), subject to APIL’s right to control such action.
Where Purchaser so joins such an enforcement action, Purchaser and APIL will share all costs and expenses thereof equally and will also share any recovery from such action equally. APIL shall not enter into any settlement agreement that would
materially harm Purchaser’s rights pursuant to this Agreement without Purchaser’s prior written consent, which shall not be unreasonably withheld, delayed or conditioned. Both APIL and Purchaser shall promptly notify the other party, as
applicable, of any infringing activity of which they are aware with respect to any of the Nanotechnology Patents and OCR Patents within the scope of an exclusive license granted to Purchaser pursuant to this Agreement to the Meloxicam Parenteral
Formulation, Meloxicam IV/IM, the BiDil Products, the Focalin Products, the Ritalin Products, the Paladin Products, the Verapamil Products or the Zogenix Products (an “Infringing Activity”). 

To the extent that APIL declines to Enforce any such issued patent within the Nanotechnology Patents and the OCR Patents with respect to an
Infringing Activity, Purchaser shall have the option to Enforce such patent, at its own cost and expense, provided that Purchaser can demonstrate to APIL’s reasonable satisfaction that (i) Purchaser is contractually obligated under a
Transferred Agreement to Enforce, or to allow the counterparty to such Transferred Agreement to Enforce, such patent with respect to such Infringing Activity or (ii) (A) permitting the Infringing Activity would have a materially adverse
effect on Purchaser’s and its sublicensees’ sales of the product exclusively licensed under such patent, and (B) based on a due care determination, including obtaining competent legal advice, the Infringing Activity exists. In such
cases, Purchaser will have sole control of such enforcement at its cost and expense. To the extent necessary, APIL will cooperate with Purchaser, at Purchaser’s cost and expense, to carry out such enforcement, including joining as a party. APIL
shall also have the right, at its option and its cost and expense, to join in any such enforcement action taken by Purchaser, subject to Purchaser’s right to control such action. For 

  
 -3- 

 
any recovery from an enforcement action involving a patent within the Nanotechnology Patents or OCR Patents, APIL shall be entitled to fifty percent (50%) of such recovery, provided however,
that fifty percent (50%) of the legal fees, costs and expenses of such enforcement action incurred by Purchaser shall be deducted from APIL’s portion of the recovery. Purchaser shall not enter into any settlement agreement regarding the
Nanotechnology Patents and OCR Patents without APIL’s prior written consent which shall not be unreasonably withheld, delayed or conditioned. 

The Parties agree that with respect to Purchaser’s obligations to Zogenix, Inc. under the Zogenix Agreements the Abuse Resistant Patents
shall be deemed to be “Elan Patents” (pursuant to clause (d) of the definition of Elan Patents under the License Agreement between APIL and Zogenix, Inc. dated November 27, 2007, as amended). 

 

	 	6.	Assignment of Abuse Resistant Patents. After the Amendment Effective Date, APIL shall execute, or procure the execution of, such formal documents of sale and/or assignment as are required consistent with the
terms and conditions of the Agreement to formally record the change of title to the Abuse Resistant Patents to Purchaser in a timely manner. 

  

	 	7.	BeadTekTM Trademark. As of the Amendment Effective Date, the BeadTekTM application shall be deemed to be included within the Transferred Trademarks and shall no longer be deemed to be a Licensed
Trademark. After the Amendment Effective Date, APIL shall execute, or procure the execution of, such formal documents of sale and/or assignment as are required consistent with the terms and conditions of the Agreement to formally record the change
of title to the BeadTekTM application to Purchaser in a timely manner. 

  

	 	8.	Integration. Except as amended herein, the Agreement shall remain in full force and effect in accordance with its terms. In the event of a conflict between the provisions of the Agreement and those of this
Amendment, this Amendment shall control. This Amendment, together with the Agreement, represents the entire agreement between the parties regarding the subject matter hereof. No amendment or modification of the terms and conditions of this Amendment
shall be binding on either party unless reduced to a writing referencing this Amendment and signed by an authorized representative of the party to be bound. 

  

	 	9.	Governing Law. This Amendment shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any principles, statutory provisions or other rules of choice of law
that would require the application of the laws of a different state or country. 

  

	 	10.	Counterparts. For the convenience of the parties, this Amendment may be executed by facsimile and in counterparts, each of which shall be deemed to be an original, and both of which taken together shall
constitute one agreement binding on both parties. 

  
 -4- 

 IN WITNESS WHEREOF, each of the parties hereto has caused its duly authorized representative to
execute this Amendment as of the date first set forth above. 
  

			
	ALKERMES PHARMA IRELAND LIMITED
		
	By:	 	 /s/ Richard Paul

	Name:	 	Richard Paul
	Title:	 	Director
	
	RECRO GAINESVILLE LLC
		
	By:	 	 /s/ Randall J. Mack

	Name:	 	Randall J. Mack
	Title:	 	SVP, Development

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]